Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CING
CING
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CING News
ABIVAX and Others See Significant Stock Gains
Jun 04 2026
NASDAQ.COM
Bluejay Diagnostics Partners with Argonaut, Shares Surge 100%
Jun 03 2026
NASDAQ.COM
Cingulate Receives Complete Response Letter from FDA for ADHD Drug
Jun 02 2026
NASDAQ.COM
Cingulate Receives FDA Response, Plans Prompt Information Submission
Jun 02 2026
Newsfilter
Cingulate Reports Increased Q1 Net Loss Amid Cash Growth
May 14 2026
seekingalpha
Cingulate Reports Slight Increase in Q4 Net Loss
Mar 18 2026
seekingalpha
Cingulate's ADHD Drug Patent Approved by USPTO
Mar 16 2026
stocktwits
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
Jan 23 2026
NASDAQ.COM
Roth Capital Reaffirms Buy Rating on Cingulate, Reduces Price Target to $16
Nov 19 2025
Benzinga
INBX Rises 81% Following Study Results; FEMY, CING, CYH Surge in After-Hours Trading
Oct 24 2025
NASDAQ.COM
Cingulate's Top ADHD Candidate CTx-1301 Chosen for Podium Presentation at AACAP Annual Meeting
Oct 23 2025
Newsfilter
Roth Capital Reaffirms Buy Rating on Cingulate, Increases Price Target to $17
Oct 15 2025
Benzinga
Cingulate Forms Exclusive Manufacturing Alliance with Bend Bio Sciences for Upcoming ADHD Treatment Commercialization
Sep 17 2025
Newsfilter
Ascendiant Capital Reiterates Buy Rating on Cingulate and Increases Price Target to $62
Aug 22 2025
Benzinga
Cingulate Reports Increased Losses in Q2
Aug 19 2025
NASDAQ.COM
Cingulate Inc. Announces Financial Results for Q2 2025 and Shares Recent Developments
Aug 19 2025
Newsfilter
Show More News
